At the end of August 2015, Shanghai Hengkang Investment Limited Partnership (through its BVI company Value Measure Investment Co., Ltd.) et al concluded negotiation and agreement signing of US$ 20 million Series B round of investment to Sirnaomics Inc. USA. Jingtian & Gongcheng acts as legal counsel to the investors.
Sirnaomic USA is an R&D center for innovative drugs, and is mainly involved in the development, technical services and technology transfer of siRNAs. It owns siRNA drug development platform with unique algorithm, fully automatic high through-put siRNA drug screening system, as well as various in vitro and in vivo pharmacology evaluation systems. RNA interference technology is a major breakthrough for bio-medicine in the last decade, and is the epitome of the third revolution of medical technology. US FDA has already approved the clinical trial of TKM-Ebola, a siRNA for Ebola virus infection. Right now, there are over 20 novel drugs conducting over 30 clinical trials at different stages in the world. Multi-nationals are coming into this market. The market capitalization of the public companies in this field is rising, with more and more acquisition deals. RNA drugs have become a heated market segment recently.
This round of investment is structured according to Delaware Corporation Law. As legal counsel of the investors, Jingtian & Gongcheng leads the design of deal structure and drafting of the full set of documentation. Through negotiation, it wins for B-round investor more benefits and legal protection compared to A-round investors, and thus wins trust and acclaims from the clients.
As a leading law firm in the medical and healthcare sector, Jingtian & Gongcheng has been providing outstanding legal services in listing, M&A, PE financing of medicine, medical device and technology, hospitals, medical garbage treatment, etc. Jingtian & Gongcheng focuses on the research and innovation on cutting edge issues in the industry, and strives to provide creative solutions that is both practical and in the best interests of its customers.
